I would be very (pleasantly) surprised if they gave any hints as to how the trial is doing. It could be stopped for overwhelming efficacy but that is usually the exception, not the rule. I fully expect it to continue. Anything better than that would be a gift.
As the man said, it's because you're an imbecile...
30 Institutional Holders
1,600,404 Total Shares Held
You're a disappointment and no one cares how much money you lost. Now begone!
The shorts here are comical at best, an annoyance at worst. Nothing they do or say will affect the pps. Even articles like Pearson's attack on ADXS ended up as a footnote. Check ADXS pps today. It could happen to GALE soon.
You'd trust someone who said this?
pine.butt Mar 14, 2015 9:20 AM
"Promises, promises ....... there will be no ebola trial.
It was just hype while ebola was in the news.
INO has a history of hyping cures for whatever illness is in the news but developing nothing."
Inovio's DNA-based vaccine against Ebola, with the first patient expected to be dosed in 2Q 2015. In previously published preclinical testing, Inovio's DNA-based Ebola vaccine protected 100% of vaccinated animals from death and sickness after being exposed to a lethal dose of the Ebola virus.
Be thankful you don't invest in stocks, your market calls have been abysmal. Consider reaching out to more experienced investors here for guidance. Bom't let pride stand in your way.
Do you have ANY idea of what you're talking about? God, you people can be so dense.
"Patient recruitment continues to be in line with our goal of ensuring the first interim analysis in the first half of this year, which will be at 128 events.
By year end, the second interim analysis of 192 events occurring will be expected or is expected. Total patient recruitment is anticipated by the end of this year, with completion of the trial by the end of 2016."